Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Operetta III: Subcutaneous Ocrelizumab in Pediatric Relapsing-Remitting Multiple Sclerosis
NCT07503340Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Oct 2026
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Roche. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT07503340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503340.